MX2020006414A - Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. - Google Patents
Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.Info
- Publication number
- MX2020006414A MX2020006414A MX2020006414A MX2020006414A MX2020006414A MX 2020006414 A MX2020006414 A MX 2020006414A MX 2020006414 A MX2020006414 A MX 2020006414A MX 2020006414 A MX2020006414 A MX 2020006414A MX 2020006414 A MX2020006414 A MX 2020006414A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- glycolate oxidase
- disease
- treatment
- oxidase inhibitors
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 6
- 201000010099 disease Diseases 0.000 title abstract 3
- 108010062584 glycollate oxidase Proteins 0.000 title abstract 3
- 102100038837 2-Hydroxyacid oxidase 1 Human genes 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000035475 disorder Diseases 0.000 abstract 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 abstract 1
- 208000004777 Primary Hyperoxaluria Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
En este documento se describen compuestos, métodos para fabricar dichos compuestos, composiciones farmacéuticas y medicamentos que contienen dichos compuestos, y métodos para usar dichos compuestos para tratar o prevenir enfermedades o trastornos asociados con la enzima glicolato oxidasa (GO). Dichas enfermedades o trastornos incluyen, por ejemplo, trastornos del metabolismo del glioxilato, incluida la hiperoxaluria primaria, que están asociados con la producción de cantidades excesivas de oxalato.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762611995P | 2017-12-29 | 2017-12-29 | |
| US201862765313P | 2018-08-20 | 2018-08-20 | |
| PCT/US2018/067784 WO2019133770A2 (en) | 2017-12-29 | 2018-12-28 | Glycolate oxidase inhibitors for the treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020006414A true MX2020006414A (es) | 2020-09-17 |
Family
ID=65234672
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020006414A MX2020006414A (es) | 2017-12-29 | 2018-12-28 | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. |
| MX2022016463A MX2022016463A (es) | 2017-12-29 | 2020-07-13 | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. |
| MX2022016427A MX2022016427A (es) | 2017-12-29 | 2020-07-13 | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. |
| MX2022016434A MX2022016434A (es) | 2017-12-29 | 2020-07-13 | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. |
| MX2022016422A MX2022016422A (es) | 2017-12-29 | 2020-07-13 | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. |
| MX2022016415A MX2022016415A (es) | 2017-12-29 | 2020-07-13 | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022016463A MX2022016463A (es) | 2017-12-29 | 2020-07-13 | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. |
| MX2022016427A MX2022016427A (es) | 2017-12-29 | 2020-07-13 | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. |
| MX2022016434A MX2022016434A (es) | 2017-12-29 | 2020-07-13 | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. |
| MX2022016422A MX2022016422A (es) | 2017-12-29 | 2020-07-13 | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. |
| MX2022016415A MX2022016415A (es) | 2017-12-29 | 2020-07-13 | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11384055B2 (es) |
| EP (1) | EP3732167A2 (es) |
| JP (2) | JP7344878B2 (es) |
| KR (1) | KR20200112860A (es) |
| CN (6) | CN117069712A (es) |
| AR (1) | AR114070A1 (es) |
| AU (1) | AU2018395275A1 (es) |
| BR (1) | BR112020013073A2 (es) |
| CA (1) | CA3086401A1 (es) |
| CL (1) | CL2020001742A1 (es) |
| IL (3) | IL297788A (es) |
| MA (1) | MA51418A (es) |
| MX (6) | MX2020006414A (es) |
| PE (1) | PE20201500A1 (es) |
| SG (1) | SG11202005807QA (es) |
| TW (2) | TW202340155A (es) |
| WO (1) | WO2019133770A2 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020006414A (es) * | 2017-12-29 | 2020-09-17 | Biomarin Pharm Inc | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. |
| US11389456B2 (en) | 2018-02-23 | 2022-07-19 | Oxalurx, Inc. | Compounds and methods for treating oxalate-related diseases |
| BR112021000050A2 (pt) * | 2018-07-06 | 2021-04-06 | Orfan Biotech Inc. | Inibidores de triazol glicolato oxidase |
| BR112022003358A2 (pt) * | 2019-08-22 | 2022-05-17 | Oxalurx Inc | Composto, composição farmacêutica, método para inibir atividade de glicolato oxidase (gox) em uma amostra biológica, método para tratar uma doença relacionada ao oxalato em um indivíduo que necessita do mesmo, e uso de um composto |
| AU2020376792B2 (en) * | 2019-11-01 | 2025-10-02 | Lilac Therapeutics, Inc. | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors |
| EP4087836B1 (en) * | 2020-01-08 | 2025-10-08 | Cantero Therapeutics, Inc. | Processes for preparing triazole glycolate oxidase inhibitors |
| CN115702146B (zh) * | 2020-06-30 | 2024-10-18 | 苏州恩华生物医药科技有限公司 | 5-((1,2,3,4-四氢异喹啉-7-基)氨基)吡啶-2(1h)-酮衍生物及其应用 |
| AU2021320147A1 (en) | 2020-08-04 | 2023-03-30 | Calcilytix Therapeutics, Inc. | Formulations of triphenyl calcilytic compounds |
| WO2022066933A1 (en) * | 2020-09-24 | 2022-03-31 | Chinook Therapeutics Canada, Inc. | Pentafluoro-sulfanyl -substituted triazolyl compounds and methods of use thereof |
| CN114478210A (zh) * | 2022-02-26 | 2022-05-13 | 江苏壹药新材料有限公司 | 一种7-氯萘-2-甲醛的合成方法 |
| WO2023170024A1 (en) * | 2022-03-11 | 2023-09-14 | University Of Copenhagen | Camk2 modulators and their use in medicine |
| GB202213162D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Prodrugs |
| WO2024109917A1 (zh) * | 2022-11-25 | 2024-05-30 | 西藏海思科制药有限公司 | 一种三唑衍生物及其在医药上的应用 |
| WO2024212137A1 (en) * | 2023-04-12 | 2024-10-17 | Cantero Therapeutics, Inc. | Crystalline forms of a 1h-1, 2, 3-triazole-4-carboxylic acid compound |
| WO2025206002A1 (ja) * | 2024-03-28 | 2025-10-02 | 日本曹達株式会社 | トリアゾール化合物および農園芸用殺菌剤 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US149223A (en) * | 1874-03-31 | Improvement in axles for vehicles | ||
| EP0002562B1 (en) * | 1977-11-10 | 1981-05-20 | Beecham Group Plc | Triazolo-quinoline derivatives, processes for their preparation and their pharmaceutical use |
| DE2757929A1 (de) * | 1977-12-24 | 1979-07-05 | Boehringer Sohn Ingelheim | Neue pyrido-eckige klammer auf 1,2-a eckige klammer zu -v-triazolo- eckige klammer auf 4,5-d eckige klammer zu pyrimidinone, deren salze und verfahren zu deren herstellung |
| JPS5519292A (en) * | 1978-07-24 | 1980-02-09 | Beecham Group Ltd | Benzopyranotriazoles*their manufacture and medical composition containing them |
| EP0007727B1 (en) | 1978-07-24 | 1983-11-30 | Beecham Group Plc | Benzopyranotriazoles, preparation of these compounds and pharmaceutical composition containing them |
| US4431660A (en) * | 1979-06-11 | 1984-02-14 | Merck & Co., Inc. | (4'-Biphenylyloxy and-thio-oxy)-3-hydroxy-3-pyrroline-2,5-diones and a method of treating calcium oxalate renal lithiasis therewith |
| US4349561A (en) | 1979-11-05 | 1982-09-14 | Merck & Co., Inc. | 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase |
| IL61897A (en) * | 1980-01-19 | 1984-01-31 | Beecham Group Ltd | Benzopyrano(2,3-d)-v-triazoles,their production and pharmaceutical compositions containing them |
| DE3169772D1 (de) * | 1980-01-19 | 1985-05-15 | Beecham Group Plc | Substituted benzopyranotriazoles |
| NZ199139A (en) * | 1980-12-13 | 1985-01-31 | Beecham Group Ltd | Benz(phenoxyalkoxy)-9-oxo-1h,9h-benzopyrano-(2,3-d)-v-triazoles |
| US4431652A (en) | 1980-12-29 | 1984-02-14 | Merck & Co., Inc. | 4-Hydroxy-5-substituted-3(2H)-isothiazolone-1,1-dioxide derivatives useful in treating urinary tract calcium oxalate lithiasis |
| US4428956A (en) | 1980-12-29 | 1984-01-31 | Merck & Co., Inc. | 4-Hydroxy-5-substituted-3-(2H)-isothiazolone-1,1-dioxide derivatives useful in treating urinary tract calcium oxalate lithiasis |
| JPS57158788A (en) * | 1981-03-03 | 1982-09-30 | Beecham Group Ltd | Novel compound, manufacture and medicinal composition containing same |
| WO1993017681A1 (en) * | 1992-03-02 | 1993-09-16 | Abbott Laboratories | Angiotensin ii receptor antagonists |
| JPH0717861A (ja) * | 1993-07-05 | 1995-01-20 | Sankyo Co Ltd | 尿路結石防止剤 |
| DK1026167T3 (da) * | 1997-09-29 | 2003-05-26 | Meiji Seika Kaisha | Tricykliske triazolobenzazepinderivater, fremgangsmåde til fremstilling af disse samt antiallergiske midler |
| JP2004532234A (ja) | 2001-04-27 | 2004-10-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | トリアゾール由来キナーゼインヒビターおよびその使用 |
| JP4075357B2 (ja) * | 2001-11-15 | 2008-04-16 | 宇部興産株式会社 | ４，５−ジ置換−１，２，３−トリアゾール及びその製造法 |
| BR0317230A (pt) * | 2002-12-13 | 2005-10-25 | Smithkline Beecham Corp | Composto, composição, métodos de antagonizar uma atividade do receptor de quimiocina ccr-5, e de tratar uma infecção viral em um paciente, e, uso de um composto |
| GB0329214D0 (en) * | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Novel compounds |
| GB0603891D0 (en) | 2006-02-27 | 2006-04-05 | Syngenta Ltd | Novel herbicides |
| US8450350B2 (en) | 2010-05-05 | 2013-05-28 | Infinity Pharmaceuticals, Inc. | Triazoles as inhibitors of fatty acid synthase |
| UA109868C2 (ru) | 2012-06-20 | 2015-10-12 | Ф. Хоффманн-Ля Рош Аг | Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar) |
| TW201418242A (zh) * | 2012-10-26 | 2014-05-16 | Du Pont | 作為除草劑之經取代的三唑 |
| KR101537296B1 (ko) * | 2012-10-26 | 2015-07-17 | 삼성전자 주식회사 | 반도체 나노결정 및 그 제조방법 |
| JP2017095366A (ja) | 2015-11-18 | 2017-06-01 | 持田製薬株式会社 | 新規ビアリールアミド誘導体 |
| EP3386967A4 (en) * | 2015-12-07 | 2020-03-25 | Wake Forest University Health Sciences | COMBINATIONS FOR TREATING KIDNEY STONES |
| EP3386949A4 (en) * | 2015-12-07 | 2019-11-20 | Wake Forest University Health Sciences | GLYCOLATE OXIDASE INHIBITORS AND METHOD FOR USE FOR THE TREATMENT OF NIERSTEIN |
| CN105669569B (zh) * | 2016-03-03 | 2017-12-12 | 武汉工程大学 | 一种nh‑1,2,3‑三唑化合物的合成方法 |
| CN105541796B (zh) * | 2016-03-03 | 2017-11-14 | 武汉工程大学 | 一种nh‑1,2,3‑三唑联吡啶化合物的合成方法 |
| MX2020006414A (es) * | 2017-12-29 | 2020-09-17 | Biomarin Pharm Inc | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. |
| CA3143334A1 (en) * | 2019-06-19 | 2020-12-24 | Biomarin Pharmaceutical Inc. | Glycolate oxidase inhibitors for the treatment of disease |
-
2018
- 2018-12-28 MX MX2020006414A patent/MX2020006414A/es unknown
- 2018-12-28 MA MA051418A patent/MA51418A/fr unknown
- 2018-12-28 SG SG11202005807QA patent/SG11202005807QA/en unknown
- 2018-12-28 CN CN202310936523.6A patent/CN117069712A/zh active Pending
- 2018-12-28 TW TW112107812A patent/TW202340155A/zh unknown
- 2018-12-28 TW TW107147699A patent/TWI811282B/zh not_active IP Right Cessation
- 2018-12-28 CN CN202310936668.6A patent/CN117126152A/zh active Pending
- 2018-12-28 WO PCT/US2018/067784 patent/WO2019133770A2/en not_active Ceased
- 2018-12-28 IL IL297788A patent/IL297788A/en unknown
- 2018-12-28 JP JP2020535997A patent/JP7344878B2/ja active Active
- 2018-12-28 EP EP18840000.6A patent/EP3732167A2/en not_active Withdrawn
- 2018-12-28 BR BR112020013073-7A patent/BR112020013073A2/pt not_active IP Right Cessation
- 2018-12-28 CA CA3086401A patent/CA3086401A1/en active Pending
- 2018-12-28 AU AU2018395275A patent/AU2018395275A1/en not_active Abandoned
- 2018-12-28 AR ARP180103914A patent/AR114070A1/es not_active Application Discontinuation
- 2018-12-28 CN CN201880090533.XA patent/CN111788187A/zh active Pending
- 2018-12-28 CN CN202310936652.5A patent/CN117069713A/zh active Pending
- 2018-12-28 CN CN202310936618.8A patent/CN117126151A/zh active Pending
- 2018-12-28 KR KR1020207022038A patent/KR20200112860A/ko not_active Ceased
- 2018-12-28 CN CN202310936604.6A patent/CN117024420A/zh active Pending
- 2018-12-28 US US16/958,511 patent/US11384055B2/en active Active
- 2018-12-28 IL IL297802A patent/IL297802A/en unknown
- 2018-12-28 PE PE2020000860A patent/PE20201500A1/es unknown
-
2020
- 2020-06-18 IL IL275496A patent/IL275496A/en unknown
- 2020-06-25 CL CL2020001742A patent/CL2020001742A1/es unknown
- 2020-07-13 MX MX2022016463A patent/MX2022016463A/es unknown
- 2020-07-13 MX MX2022016427A patent/MX2022016427A/es unknown
- 2020-07-13 MX MX2022016434A patent/MX2022016434A/es unknown
- 2020-07-13 MX MX2022016422A patent/MX2022016422A/es unknown
- 2020-07-13 MX MX2022016415A patent/MX2022016415A/es unknown
-
2022
- 2022-05-23 US US17/751,144 patent/US20230089374A1/en not_active Abandoned
- 2022-05-23 US US17/751,136 patent/US20230079913A1/en not_active Abandoned
-
2023
- 2023-08-04 JP JP2023127874A patent/JP2023159181A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022016463A (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. | |
| MX2021015874A (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. | |
| PH12019500521A1 (en) | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
| MX2023003677A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| EP4219713A3 (en) | Products and compositions | |
| MX2023003678A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| BR112016029041A2 (pt) | terapia de combinação com inibidores de glutaminase | |
| EA201791874A1 (ru) | Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение | |
| PH12016501600A1 (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| MX2022001310A (es) | Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo. | |
| MX2022005775A (es) | Compuestos terapeuticos y metodos de uso. | |
| PH12022551105A1 (en) | Tyk2 pseudokinase ligands | |
| MX2021009555A (es) | Ligandos de pseudocinasa tyk2. | |
| MX370270B (es) | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. | |
| MX2022000712A (es) | Moduladores de nlrp3. | |
| MX2021011723A (es) | Ligandos de pseudocinasa tyk2. | |
| MX2020007586A (es) | Proceso de fabricacion de moduladores de somatostatina. | |
| MX2021011507A (es) | Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento. | |
| PH12022551052A1 (en) | Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor | |
| MX2019004859A (es) | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. | |
| MX2023001296A (es) | Composiciones y metodos para tratar enfermedades y trastornos. | |
| MX2019006863A (es) | Inhibidores de heparanasa y uso de los mismos. | |
| MX2023003675A (es) | Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| WO2020068950A8 (en) | Hdac1,2 inhibitors | |
| MA43158B1 (fr) | Composés oxa-diazadispiro possédant une activité contre la douleur |